Characteristics and prognosis of patients with elevated triglycerides in acute myocardial infarction: observational data from a large database over a 17-year period: High triglycerides in acute myocardial infarction.

From a large regional registry, we aimed to address the characteristics and prognosis of patients with elevated triglycerides (TG) among patients hospitalized for an acute myocardial infarction (MI). From the multicenter database of the RICO survey, all consecutive patients hospitalized for an acute MI (2001-2017) and alive at discharge were included. Among the 10,667 patients included, 17.7% had elevated TG. When compared with patients with TG ≤ 200 mg/dL, patients with high TG (>200 mg/dL) were 10 years younger, had a higher BMI, were more frequently men, diabetic, and smokers. At 1-year follow-up, recurrent ischemic events were more frequent in elevated TG patients. In multivariate logistic regression analysis, high TG (OR (95%CI): 1.356 (1.095-1.679)) remained an independent estimate for recurrent ischemic events, even after adjustment for confounding factors. In our large population-based cohort, elevated TG are common in acute MI, and associated with residual risk of recurrent ischemic events, beyond traditional prognostic markers.

Informations de copyright

Copyright © 2023. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Disclosure of conflict of interest MF reports having received grants, consulting fees and/or honoraria and delivering lectures for Abbott, Amarin, Amgen, AstraZeneca, Ajanta, Kowa, Merck and Co, Novartis, Organon, Pfizer, Recordati, Sanofi/Regeneron, Servier, SMB, Ultragenyx and Viatris. FC reports having received non-financial support and speaking fees for Amgen, MSD, Novartis, Sanofi and Pfizer. YC reports having received consultant or speaking fees for Bayer, BMS/Pfizer, Boehringer Ingelheim, Novartis, Sanofi and Servier. MZ declare research grants from Amarin Corp and speaking fees from Organon and Amgen. No declaration for the other authors.